Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years.

The first year’s retention rate regarding the second biologic showed a significant trend to decrease, both in terms of patients overall, from 55.3%, in the first period to 46.15% in the fourth ( p < 0.001), and by pathologies (Table 4 ).

also in 9,775 other papers